Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced on 4/17/19 the... read more
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced on 4/17/19 the... read more
On 4/16/19, Flagship Pioneering, unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief executive officer, and member of the board of directors. Kintai is... read more
Cortexyme has filed for an $86 million IPO. The company is developing treatments for neurodegenerative diseases based on the discovery of pathogenic bacteria in the brains of Alzheimer's patients... read more
Early stage biotech, Axcella Health, has filed for an $86 million IPO. The initial filing documents do not provide the number of shares in the offering or the expected price range. The company has... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,